CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini on Monday, April 29th. As previously communicated, the Immucor assay and sample requirements are the same, and the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list are now available on our website.
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...